# DESCRIPTION

## BACKGROUND OF THE INVENTION

- introduce SphK2 inhibitors
- describe S1P and its biosynthetic precursors
- discuss SphK1 and SphK2 differences
- summarize SphK1 functions
- discuss SphK2 functions
- highlight need for SphK2-selective inhibitors
- describe existing SphK inhibitors
- emphasize need for new SphK2 inhibitors

## SUMMARY OF THE INVENTION

- introduce 5-alkylidenethiazolidine-2,4-dione and 3-alkylidene-1,3-d
- describe Formula I compounds
- define R1, R2, R3, R4, R5, V, X, Y, Z, and W
- introduce Formula II compounds
- define R10, R11, R12, R13, R14, R15, R16, R17, R18, X,
- describe methods of treating cancer
- specify compounds for treating cancer
- describe methods of inhibiting SphK2
- specify compounds for inhibiting SphK2
- describe methods of treating cancer with Formula I compounds
- describe methods of treating cancer with Formula II compounds
- specify cancer types
- describe methods of inhibiting SphK2 with Formula I compounds
- describe methods of inhibiting SphK2 with Formula II compounds
- specify W as NH2
- specify R1 alkoxyl substituent with 4, 7, or 8 carbon atoms
- describe Formula III and Formula IV compounds
- specify KL145 and KLlll016 compounds
- describe methods of treating cancer with Formula III and Formula IV
- describe methods of inhibiting SphK2 with Formula III and Formula IV
- summarize invention objectives

## DETAILED DESCRIPTION

- disclose compounds

### In Formula I:

- define R1
- define R2-R5
- define V
- define X and Y
- define Z
- define W
- define Formula II
- define terms and embodiments
- describe compounds of Formula I and Formula III
- describe structural characterization of compounds
- list compounds that inhibit SphK2
- describe selective inhibition of SphK2
- describe non-selective inhibition of SphK1 and SphK2
- introduce compositions for treating diseases associated with SphK2
- describe composition components
- list pharmaceutical additives and excipients
- describe acidifying agents
- describe alkalinizing agents
- describe adsorbents
- describe aerosol propellants
- describe air displacement agents
- describe antifungal preservatives
- describe antimicrobial preservatives
- describe antioxidants
- describe binding materials
- describe buffering agents
- describe carrying agents
- describe chelating agents
- describe colorants
- describe clarifying agents
- describe emulsifying agents
- describe encapsulating agents
- describe fillers
- describe flavorants
- describe humectants
- describe additional additives and excipients
- describe methods of treating cancer
- define compound administration
- specify dosage range
- describe administration protocols
- define effective amount
- describe treatment benefits
- list treatable cancer types
- specify patient subjects
- describe SphK2 inhibition methods
- specify inhibition levels
- describe measuring inhibition
- describe selective SphK2 inhibition
- describe non-selective SphK1 and SphK2 inhibition
- describe cell growth inhibition methods
- describe treating diseases associated with SphK2
- introduce non-limiting examples

## EXAMPLES

- describe synthesis of compounds

### Example 1

- prepare compound 26

### Example 2

- prepare compound 27

### Example 3

- prepare compounds 28-36

### Example 4

- prepare 4-alkoxyphenylpropanal compounds 14-19
- perform alkoxylation reaction

### Example 5

- prepare 4-alkoxybenzaldehyde compounds 2-7

### Example 6

- prepare compounds 24, 46, 48, and 50 by Swern oxidation

### Example 7

- prepare compound 39 by reduction

### Example 8

- prepare guanidine analog 42

### Compounds 28-36 39-40 and 42 of Schemes 2 and 3

- provide example 9
- provide NMR data for KII167 (42)
- provide example 10
- provide NMR data for KLIII16 (31)
- provide example 11
- provide NMR data for KLII157 (32)
- provide example 12
- provide NMR data for KLII123 (33)
- provide example 13
- provide NMR data for KLII147 (35)
- provide example 14
- provide NMR data for KLII139 (34)
- provide examples 15-25
- provide NMR data for examples 15-25
- describe compounds 28-36, 39-40, and 42 of Schemes 2 and 3
- provide NMR data for Example 26
- provide NMR data for Example 27
- provide NMR data for Example 28
- provide NMR data for Example 29
- provide NMR data for Example 30
- provide NMR data for Example 31
- provide NMR data for Example 32
- describe in vitro test for SphK1 and SphK2
- describe kinetic studies of Formula III (K145)
- describe cell viability assays in human leukemia U937 cells
- describe Western blot analysis
- describe cell apoptosis assays
- describe in vivo studies for anti-proliferation of U937 xenografts in nude mice
- describe in vivo studies for anti-growth of JC xenografts in syngenic BALB/c mice
- describe in vivo studies for anti-proliferation of U937 xenografts in nude mice by K145 through oral administration
- describe in vitro target validation of K145
- describe uptake of K145 by U937 cells
- describe effect of K145 on cellular levels of S1P
- describe effect of K145 on ceramide levels
- describe effect of K145 on ceramide-1-phosphate levels
- describe effect of K145 on phosphorylation of FTY720
- describe results of FIG. 1
- describe results of FIG. 2
- describe results of FIG. 7
- describe results of FIG. 8
- describe results of FIG. 9
- describe results of FIGS. 10-16

